Javascript must be enabled to continue!
Recurrence pattern for superficial bladder cancer
View through CrossRef
Aim: Patients with superficial bladder tumors sometimes have long recurrence‐free intervals. We evaluated whether patients with long recurrence‐free periods had subsequent recurrences. We also clarified how these patients should be followed.Materials and methods: We enrolled 244 patients with superficial bladder cancer (62 pTa and 182 pT1) treated by transurethral resection of bladder tumor (TURBT) and adjuvant chemotherapy with pirarubicin. Median follow up was 75.5 months. Patients were stratified by the length of their recurrence‐free interval.Results: Recurrences occurred in 124 patients (50.8%). Of 185 patients who did not have a recurrence for the first 3 years, subsequent recurrences occurred in 65 patients; in more than half the first recurrence developed after 5 years or more. Ta tumors had a low recurrence rate (14.5%) with the first recurrence often developing after a long recurrence‐free period. Of 40 patients who remained recurrence‐free for 3 years or more after at least one recurrence occurred, 16 patients (40%) had subsequent recurrences. Furthermore, most of these patients who remained free of recurrence for more than 5 years eventually had a recurrence. The overall progression rate was 15.6%, and this did not relate to the length of the recurrence‐free interval.Conclusion: When patients did not have a recurrence for the first 3 years, tumors subsequently often recurred, even in pTa tumors. In patients with at least once recurrence, subsequent recurrences appear to occur irrespective of the length of the recurrence‐free period. Thus, we recommend that all patients with superficial bladder tumors be followed for as long as possible.
Title: Recurrence pattern for superficial bladder cancer
Description:
Aim: Patients with superficial bladder tumors sometimes have long recurrence‐free intervals.
We evaluated whether patients with long recurrence‐free periods had subsequent recurrences.
We also clarified how these patients should be followed.
Materials and methods: We enrolled 244 patients with superficial bladder cancer (62 pTa and 182 pT1) treated by transurethral resection of bladder tumor (TURBT) and adjuvant chemotherapy with pirarubicin.
Median follow up was 75.
5 months.
Patients were stratified by the length of their recurrence‐free interval.
Results: Recurrences occurred in 124 patients (50.
8%).
Of 185 patients who did not have a recurrence for the first 3 years, subsequent recurrences occurred in 65 patients; in more than half the first recurrence developed after 5 years or more.
Ta tumors had a low recurrence rate (14.
5%) with the first recurrence often developing after a long recurrence‐free period.
Of 40 patients who remained recurrence‐free for 3 years or more after at least one recurrence occurred, 16 patients (40%) had subsequent recurrences.
Furthermore, most of these patients who remained free of recurrence for more than 5 years eventually had a recurrence.
The overall progression rate was 15.
6%, and this did not relate to the length of the recurrence‐free interval.
Conclusion: When patients did not have a recurrence for the first 3 years, tumors subsequently often recurred, even in pTa tumors.
In patients with at least once recurrence, subsequent recurrences appear to occur irrespective of the length of the recurrence‐free period.
Thus, we recommend that all patients with superficial bladder tumors be followed for as long as possible.
Related Results
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract
Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Purines modulate urinary bladder arteriolar tone
Purines modulate urinary bladder arteriolar tone
Bladder dysfunction affects millions of people, but few effective treatments are available. In humans, changes in bladder function correlate to changes in blood flow. In rodent mod...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Urinary bladder wall thickness in type 2 diabetes mellitus patients
Urinary bladder wall thickness in type 2 diabetes mellitus patients
Introduction: Diabetes mellitus is an increasing health challenge with accompanying urological complications. Over 50% of men and women with diabetes have bladder dysfunction. Acco...
Abstract 4948: Bladder cancer incidence: A systematic review and meta-analysis in SSA
Abstract 4948: Bladder cancer incidence: A systematic review and meta-analysis in SSA
Abstract
Introduction:
Bladder Cancer shows a substantial geographic disparity worldwide (1-3). The highest incidence rates are ...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...

